The Starpharma Holdings Limited (ASX: SPL) share price was up 6% to $1.16 on Wednesday, after the company announced a major deal for the distribution of one of its flagship products.
Starpharma signed an agreement with Mundipharma for the sale and marketing of its feminine care product VivaGel BV in several overseas markets including Europe and Russia.
The deal extends the global reach of the medicine, expanding an existing agreement with Mundipharma that covered Asia, the Middle East, Africa and Latin America. Mundipharma will launch VivaGel under its popular antiseptic brand Betadine in early 2019.
Europe in particular is an important market in which Starpharma is ready to tap into, having already obtained the necessary regulatory approvals. Starpharma will receive a share of sales revenue, and up to $33 million of conditional revenue on commercial milestones.
Starpharma is also preparing to launch VivaGel in North America and has lodged an application with the US Food and Drug Administration.
The distribution of VivaGel could prove vital in boosting the company’s earnings. In FY17, Starpharma reported a profit thanks to the sale of its Agrochemicals business, but flagged a $15 million loss on its continuing operations. The trend continued in FY18, with a half-year loss of $6 million.
But there are other companies that are growing their profits and increasing dividends. Click here to learn more.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor Tommaso Autorino has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.